Athira Pharma (ATHA)
(Delayed Data from NSDQ)
$0.43 USD
0.00 (-0.16%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.42 -0.01 (-1.18%) 7:28 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.43 USD
0.00 (-0.16%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.42 -0.01 (-1.18%) 7:28 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Zacks News
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
by Zacks Equity Research
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
by Zacks Equity Research
Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?
by Zacks Equity Research
Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
by Zacks Equity Research
Athira (ATHA) completes dosing the last patient in the phase II/III LIFT-AD study on fosgonimeton for treating people with mild-to-moderate Alzheimer's disease. Stock gains.
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Stryker (SYK) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
by Zacks Equity Research
FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.
Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View
by Zacks Equity Research
Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View
by Zacks Equity Research
Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.
Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Athira Pharma, Inc. (ATHA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Is the Options Market Predicting a Spike in Athira Pharma (ATHA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.
Athira Pharma, Inc. (ATHA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) closed at $10.13 in the latest trading session, marking a -1.65% move from the prior day.
Athira (ATHA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus to be on the company's pipeline progress, mainly on its small molecule candidate ATH-1017 for Alzheimer's disease, on Athira's (ATHA) second-quarter earnings call.
Athira Pharma, Inc. (ATHA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) closed the most recent trading day at $10.06, moving +1.51% from the previous trading session.
Athira Pharma, Inc. (ATHA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) closed the most recent trading day at $10.04, moving -1.47% from the previous trading session.
Implied Volatility Surging for Athira Pharma (ATHA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.
Athira Pharma, Inc. (ATHA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Athira Pharma, Inc. (ATHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.